ΒΙΒΛΙΟΓΡΑΦΙΑ

1. Johnson RW, Wasner G, Saddier P et al. Postherpetic Neuralgia: epidemiology, pathology and management. Expert Rev Neurothen 2007;7: 1581-95.

2. Arvin A. Aging, immunity, and the varicella zoster virus. N. Engl J Med 2005;352:2266-67.

3. Oxman MN. Zoster Vaccine: Current Status and Future Prospects Clinical Infectious Diseases 2010;52(2): 197-213.

4. Johnson RW. Herpes Zoster and Postherpetic Neuralgia: a review of the effects of vaccination Aging Clin Exp Res 2009;21: 236-243.

5. Burke BL: Steele RW; Beard OW; Wood JS; Cain TD; Marmer DJ. Immune Responses to Varicalla-Zoster in the Aged. Arch Intern Med 1982; 42:291-293.

6. Browsher D. The lifetime occurrence of Herpes Zoster and prevalence of post-herpetic neuralgia: A retrospective survey in an elderly population. Eur J Pain 1999;3: 335-42.

7. Miller E, Marshall R, Vurdien J. Epidemiology, outcome and xontrol of varicella-zosterin- fection Rev Med Micro 1993;4: 222-30.

8. Forbes HJ, Bhaskaran K, Thomas SL, Smeeth L, Clayton T, Langan Sm. Quantification of risk factors for herpes zoster: population based case-control study. BMJ 2014;348:g2911.

9. Hope-Simpson RE. Postherpetic neuralgia. JR Coll Gen Practice 1975;25: 571-5.

10. Johnson RW et al. The impact of herpes zoster and post-herpetic neuralgia on quality-of-life. BMC Med 2010;8:1-13.

11. Helgason S, Petursson G, Gudmundsson S et al. Prevalence of postherpetic neuralgia after a single episode of herpes zoster: prospective study with long term follow up. Br Med J 2000; 321: 1-4.

12. Johnson RW. Zoster associated pain: what is known, who is at risk and how can it be managed? Herpes 2007;14 (s2): 30A-34A.

13. Weinke T et al. Impact of herpes zoster and post-herpetic neuralgia on patients’ quality of life: a patient-reported outcomes survey J Public Health 2010;18(4): 367-374.

14. Drolet M et al. The impact of herpes zoster and postherpetic neuralgia CMAJ 2010;N/A: DOI:10.1503/cmaj.091711.

15. Drolet M. Employment related productivity loss associated with herpes zoster and postherpetic neuralgia: A 6-month prospective study. Vaccine 2012;30:2047-50.

16. Cunningham AL, Breuer J, Dwyer DE et al. The prevention and management of herpes zoster. Med J Aust 2008;188: 171-6.

17. Pavan-Langston D.Ophthalmic zoster. In: Arvin AM, Gershon AA eds. Varicella-Zoster virus – Virology and clinical management. Cambridge: Cambridge University Press; 2000;N/A: p276-98.

18. Oxman MN. Clinical manifestations of herpes zoster. In: Arvin AM, Gershon AA, eds. Varicella-Zoster Virus. Virology and clinical management. Cambridge: Cambridge University Press; 2000. p. 246-75.

19. Galil K et al. The sequelae of Herpes Zoster. Arch Intern Med 1997; 157: 1209-1213.

20. Johnson R, McElhaney J, Pedalino B et al, Prevention of herpes zoster and its painful and debilitating complications. Int J Infect Dis (Supplement) 2007; 11 S2:S43-S48.

21. Katz J, Cooper EM, Walther RR, et al. Acute pain in herpes zoster and its impact on health-related quality of life. Clin Infect Dis. 2004;39(3):342–348

22. Guignard AP, Greenberg M, Lu C, Rosillon D, Vannappagari V. Risk of herpes zoster among diabetics: a matched cohort study in a US insurance claim database before introduction of vaccination, 1997-2006. Infection. 2014;42:729-35.

23. Harpaz R et al. Prevention of Herpes Zoster Recommendations of the Advisory Committee on Immunization Practices (ACIP), MMWR. 2008;RR-5):1–30.

24. Schmader KE. Epidemiology and impact on quality of life of postherpetic neuralgia and painful diabetic neuropathy. Clin J Pain. 2002;18(6):350–354.

25. Katz J, Melzack R. Measurement of pain. Surg Clin North Am. 1999;79(2):231–252

26. Johnson RW. Consequences and management of pain in herpes zoster. J Infect Dis. 2002;186(suppl 1):S83–S90.

27. Yawn BP, Saddier P, Wollan PC, et al. A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. Mayo Clin Proc. 2007;82(11):1341–1349.

28. Εγκύκλιος Υπουργείου Υγείας “Εθνικό Πρόγραμμα Ενηλίκων 2023”, Αθήνα 7/2/2023 Αρ. Πρωτοκόλλου Δ1α/Γ.Π.οικ. 7610

29. Φύλλο Οδηγιών Χρήσης Εμβολίου Έρπητα ζωστήρα (από ζώντες ιούς), Απρίλιος 2022

Αυτές οι πληροφορίες προορίζονται για γενική πληροφόρηση και ενημέρωση του κοινού και σε καμία περίπτωση δεν μπορούν να υποκαταστήσουν τη συμβουλή ιατρού ή άλλου αρμοδίου επαγγελματία υγείας.

MERCK SHARP & DOHME Α.Φ.Β.Ε.Ε
ΑΓΙΟΥ ΔΗΜΗΤΡΙΟΥ 63 ΑΛΙΜΟΣ, ΤΚ 17456
ΑρΓεΜΗ 121808101000